in vivo cDNA synthesis technologies

Invivoscribe holds exclusive rights to the following patent:
United States Patent Number 6,498,025

Managing biomarkers and associated licenses
Invivoscribe has exclusive rights to the following patent application:
United States Provisional Patent Application 61/473,716

Method for analysing a marker nucleic acid molecule

Invivoscribe Technologies holds exclusive rights to the following patent and patent applications that cover a method of analysing a rearranged immunoglobulin or T cell receptor variable region gene:
United States Patent Number 7,785,783
International Patent Application PCT/AU2004/000625
Brazil Patent Application Number PI0410283.5
Canadian Patent Application Number 2525122
European Patent Application Number 04732551.9
Indian Patent Application Number 5792/DELNP/2005
Japanese Patent Application Number 2006-529437
Mexican Patent Application Number PA/a/2005/012102
Chinese Patent Application Number 200480016603.5
Korean Patent Application Number 10-2005-7021561

Determining the replicative history of lymphocytes

A method for DNA breakpoint analysis

Invivoscribe Technologies holds exclusive rights to the following patent applications:
United States Patent Application 20090202999
United States Patent Application 20100216138
International Patent Application Number PCT/AU2008/000779

A method for DNA amplification

Invivoscribe Technologies holds exclusive rights to the following patent applications:
International Patent Application 02/10/2008
International Patent Application PCT/AU2008/001453
United States Patent Application 20100248310

A method for amplification

Invivoscribe Technologies holds exclusive rights to the following patent applications:
United States Provisional Patent Application 61/217707
United States Patent Application 20100304444

Detecting targets using nucleic acids having both a variable region and a conserved region

Invivoscribe Technologies holds exclusive rights to the following patent application:
United States Patent Application 20090209432

Method of regulating oligonucleotide functionality

Invivoscribe Technologies holds exclusive rights to the following patent application:
United States Provisional Patent Application 61/319146

Nucleic acid amplification primers for PCR-based clonality studies

Invivoscribe holds the exclusive license to intellectual property covering methods and compositions developed by the EuroClonality/BIOMED-2 Clonality Group, with the right to use and apply methods and the right to manufacture, market, offer for sale and sell products in affiliation with the BIOMED-2 Clonality Group.  Further, the license limits affiliation of BIOMED-2 Clonality Group to Invivoscribe only and allows Invivoscribe to use the name of the BIOMED-2 Clonality Group in marketing and sales materials.
Granted European Patent Number EP 1549764B1, and divisionals of underlying application 03756746.8 (applicable in 16 EU countries)
Granted Japanese Patent Number P04708029B2
United States Patent Application 10/531,106

Nucleic acid encoding receptor type protein kinase, FLT3

Invivoscribe Technologies holds the exclusive license (ex-Japan)to develop, manufacture, use, and sell testing reagents for FLT3/ITD mutation detection. We hold rights to granted patents in the U.S. and in Europe and are both prosecuting existing patent applications and preparing a number of additional patent applications covering this technology to ensure that we maximize the breadth of claims and solidify our already comprehensive IP coverage. Issued patents and patent applications currently pending that are licensed exclusively to IVS include:
United States Patent Number 6,846,630
United States Patent Number 11,892,241
Granted European Patent Number 0959132 (validated in 16 EU countries)
United States Patent Application 12/938,617
United States Patent Application 12/938,629
United States Patent Application 12/938,723
United States Patent Application 12/938,712
United States Patent Application 12/557,193

Nucleophosmin protein (NPM1) mutants, corresponding gene sequences and uses thereof

Invivoscribe holds rights to use technologies related to the following patent applications:
Canadian Patent Application 2585965
United States Patent Application 11/666,542
European Patent Application EP20050813231
Chinese Patent Application 200580045036.0